Business
Entera Bio Announces First Quarter 2025 Financial Results and Business Updates
JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025. “During Q1 2025, Entera continued to generate intrinsic value with progress across our programs while significantly extending our cash runway into late 2026 via direct investment from marquis investors and our strategic partner, OPKO Health Inc. (“O
About this update from Entera Bio Ltd.
[{"type":"image","alt":"Entera Bio Ltd.","displaySize":"","headline":null,"caption":"Entera Bio Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":164,"height":92,"url":"https://media.zenfs.com/en/globenewswire.com/ae9eba6049230107c762631bf8659d65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XGS._Ivm6nmvEHmx.FpICw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ae9eba6049230107c762631bf8659d65","width":164,"height":92}},"lazy":false},{"type":"text","content":"JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025.","length":250,"tagName":"p"},{"type":"text","content":"“During Q1 2025, Entera continued to generate intrinsic value with progress across our programs while significantly extending our cash runway into late 2026 via direct investment from marquis investors and our strategic partner, OPKO Health Inc. (“OPKO”). EB613 early mechanistic effects on both trabecular and cortical bone compartments data using 3D-Shaper software analysis was selected for oral presentation out of 1,680 abstracts submitted to the 2025 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases Congress. Subsequent EB613 abstracts have been submitted to both the 2025 American Society for Bone Mineral Research (ASBMR) and the North American Menopause Society (NAMS) conferences. Pre-IND activities for our Next Gen EB613 tablet candidate are in final stages, with plans to initiate a Phase 1 study in H2 2025. Via the execution of our recent license agreement with OPKO, we are fully funded to co-develop Oral OPK-88006 (the first dual acting GLP1/Glucagon single tablet for metabolic diseases) through SAD/MAD Phase 1 studies while retaining a 40% stake in the economics of this important asset. An abstract for Oral OPK-88006 has been submitted to ENDO2025. Finally, we are judiciously strengthening our core team with important appointments including Ms. Leslie Gautam, as Chief Business Officer and Ms. Cherin Smith as Head of Clinical Operations, both of whom have extensive experience in strategic and operational execution in women-centric conditions,” said Miranda Toledano, Chief Executive ...